<DOC>
	<DOCNO>NCT01890863</DOCNO>
	<brief_summary>This study compare pharmacokinetic ( PK ) Fluticasone Propionate/Salmeterol combination ( FSC ) 100/50 microgram ( mcg ) deliver via capsule-based inhaler ( Rdpi ) relative FSC 100/50 mcg deliver via multi-dose dry powder inhaler ( Ddpi ) establish whether Rdpi inhaler exposure ( term fluticasone propionate area time concentration curve [ AUC ] Salmeterol maximum concentration [ Cmax ] ) great 1.2500 compare Ddpi , sufficient allow progression Phase 3 . This study enroll 36 healthy adult male female subject subject allocate one two sequence participate four treatment period , receive treatment twice .</brief_summary>
	<brief_title>ROTAHALER Device Optimization Study</brief_title>
	<detailed_description />
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion Criteria Males female age 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator determines find unlikely introduce additional risk factor interfere study procedure . Body mass index within range 18 35 kilograms/meter square ( m^2 ) ( inclusive ) . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ( definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ) ; postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone &gt; 40 milli international unit/mililiter [ mL ] estradiol &lt; 40 picogram/mL [ &lt; 147 picomoles/liter ] confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 2 4 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Childbearing potential negative pregnancy test determine serum human chorionic gonadotropin ( hCG ) test screen prior dosing . Agrees use one contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 2 day postlast dose . OR samesex partner , prefer usual lifestyle . Capable give write informed consent , include compliance requirement restriction list consent form . Alanine aminotransferase , alkaline phosphatase bilirubin &lt; = 1.5xupper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based single average QT interval correct ( QTc ) value triplicate electrocardiogram ( ECGs ) obtain brief recording period : QT duration correct heart rate Fridericia 's formula ( QTcF ) &lt; 450 millisecond ( msec ) , QT duration correct heart rate Bazett 's formula ( QTcB ) &lt; 480 msec subject Bundle Branch Block . Exclusion Criteria Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . In Australia one unit ( = standard drink ) equivalent 10 gram alcohol : 270 mL full strength beer ( 4.8 % ) , 375mL mid strength beer ( 3.5 % ) , 470 mL light beer ( 2.7 % ) , 250 mL premix full strength spirit ( 5 % ) , 100 mL wine ( 13.5 % ) 30 mL spirit ( 40 % ) History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive prestudy drug/alcohol screen . A positive test human immuno virus antibody . Pregnant female determine positive serum hCG test screen prior dosing . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Lactating female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>fluticasone propionate/salmeterol</keyword>
	<keyword>PK equivalence</keyword>
	<keyword>COPD</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>fluticasone propionate/salmeterol capsule-based inhaler</keyword>
	<keyword>fluticasone propionate/salmeterol multi-dose dry powder inhaler</keyword>
	<keyword>Respiratory</keyword>
</DOC>